Annual Cash & Cash Equivalents
$42.92 M
-$47.54 M-52.55%
31 December 2023
Summary:
Akebia Therapeutics annual cash & cash equivalents is currently $42.92 million, with the most recent change of -$47.54 million (-52.55%) on 31 December 2023. During the last 3 years, it has fallen by -$185.77 million (-81.23%). AKBA annual cash & cash equivalents is now -81.23% below its all-time high of $228.70 million, reached on 31 December 2020.AKBA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$34.02 M
-$5.48 M-13.87%
30 September 2024
Summary:
Akebia Therapeutics quarterly cash and cash equivalents is currently $34.02 million, with the most recent change of -$5.48 million (-13.87%) on 30 September 2024. Over the past year, it has dropped by -$12.51 million (-26.89%). AKBA quarterly cash and cash equivalents is now -86.54% below its all-time high of $252.76 million, reached on 31 March 2021.AKBA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKBA Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -52.5% | -26.9% |
| 3 y3 years | -81.2% | -83.6% |
| 5 y5 years | -59.0% | -72.3% |
AKBA Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -81.2% | at low | -83.6% | at low |
| 5 y | 5 years | -81.2% | at low | -86.5% | at low |
| alltime | all time | -81.2% | +2515.8% | -86.5% | +60.4% |
Akebia Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $34.02 M(-13.9%) |
| June 2024 | - | $39.50 M(-5.9%) |
| Mar 2024 | - | $41.96 M(-2.2%) |
| Dec 2023 | $42.92 M(-52.6%) | $42.92 M(-7.7%) |
| Sept 2023 | - | $46.53 M(-13.1%) |
| June 2023 | - | $53.57 M(-5.9%) |
| Mar 2023 | - | $56.95 M(-37.0%) |
| Dec 2022 | $90.47 M(-39.6%) | $90.47 M(-37.5%) |
| Sept 2022 | - | $144.76 M(+0.6%) |
| June 2022 | - | $143.89 M(-17.6%) |
| Mar 2022 | - | $174.56 M(+16.5%) |
| Dec 2021 | $149.80 M(-34.5%) | $149.80 M(-27.7%) |
| Sept 2021 | - | $207.20 M(-16.1%) |
| June 2021 | - | $246.99 M(-2.3%) |
| Mar 2021 | - | $252.76 M(+10.5%) |
| Dec 2020 | $228.70 M(+55.1%) | $228.70 M(+35.1%) |
| Sept 2020 | - | $169.29 M(-31.0%) |
| June 2020 | - | $245.41 M(+112.7%) |
| Mar 2020 | - | $115.37 M(-21.8%) |
| Dec 2019 | $147.45 M | $147.45 M(+20.0%) |
| Sept 2019 | - | $122.89 M(+40.9%) |
| June 2019 | - | $87.21 M(+39.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $62.74 M(-40.0%) |
| Dec 2018 | $104.64 M(+49.2%) | $104.64 M(-35.6%) |
| Sept 2018 | - | $162.43 M(-0.7%) |
| June 2018 | - | $163.53 M(+3.4%) |
| Mar 2018 | - | $158.17 M(+125.5%) |
| Dec 2017 | $70.16 M(-62.6%) | $70.16 M(-21.7%) |
| Sept 2017 | - | $89.60 M(-28.5%) |
| June 2017 | - | $125.39 M(+43.7%) |
| Mar 2017 | - | $87.25 M(-53.4%) |
| Dec 2016 | $187.34 M(+276.3%) | $187.34 M(+184.6%) |
| Sept 2016 | - | $65.83 M(+42.6%) |
| June 2016 | - | $46.18 M(+6.3%) |
| Mar 2016 | - | $43.44 M(-12.7%) |
| Dec 2015 | $49.78 M(+51.9%) | $49.78 M(-25.4%) |
| Sept 2015 | - | $66.71 M(-12.5%) |
| June 2015 | - | $76.25 M(+173.4%) |
| Mar 2015 | - | $27.89 M(-14.9%) |
| Dec 2014 | $32.78 M(+54.5%) | $32.78 M(-34.0%) |
| Sept 2014 | - | $49.67 M(-47.9%) |
| June 2014 | - | $95.39 M(-24.5%) |
| Mar 2014 | - | $126.32 M(+495.4%) |
| Dec 2013 | $21.21 M(+1192.8%) | $21.21 M |
| Dec 2012 | $1.64 M | - |
FAQ
- What is Akebia Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Akebia Therapeutics?
- What is Akebia Therapeutics annual cash & cash equivalents year-on-year change?
- What is Akebia Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Akebia Therapeutics?
- What is Akebia Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Akebia Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AKBA is $42.92 M
What is the all time high annual cash & cash equivalents for Akebia Therapeutics?
Akebia Therapeutics all-time high annual cash & cash equivalents is $228.70 M
What is Akebia Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AKBA annual cash & cash equivalents has changed by -$47.54 M (-52.55%)
What is Akebia Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AKBA is $34.02 M
What is the all time high quarterly cash and cash equivalents for Akebia Therapeutics?
Akebia Therapeutics all-time high quarterly cash and cash equivalents is $252.76 M
What is Akebia Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, AKBA quarterly cash and cash equivalents has changed by -$12.51 M (-26.89%)